THRB and metabolic dysfunction-associated steatohepatitis: Very recently, a study reporting on a phase 3 randomized controlled trial has suggested that resmetirom, an oral liver-directed thyroid hormone receptor beta-selective agonist, could improve (delay) the evolution of liver fibrosis in individuals with non-alcoholic steatohepatitis [95].